Annals of Nuclear Medicine最新文献

{"title":"Dynamic expression of the myocardial sigma-1 receptor after doxorubicin cardiomyopathy using radioiodine-labeled 2-[4-(2-iodophenyl)piperidino]cyclopentanol (OI5 V) imaging.","authors":"Zhuoqing Chen, Hiroshi Wakabayashi, Hiroshi Mori, Tomo Hiromasa, Xue Zhang, Takashi Kozaka, Kazuma Ogawa, Seigo Kinuya, Junichi Taki","doi":"10.1007/s12149-025-02062-3","DOIUrl":"https://doi.org/10.1007/s12149-025-02062-3","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to evaluate the expression of the intensity and distribution of the sigma-1 receptor (σ1R) demonstrated by radiolabeled 2-[4-(2-iodophenyl)piperidino]cyclopentanol (OI5V) in a rat model of doxorubicin-induced cardiotoxicity.</p><p><strong>Methods: </strong>Wistar rats received doxorubicin (DOX; 2 mg/kg/week) as an intraperitoneal injection. Gated ^{99 m}Tc-MIBI SPECT was performed for cardiac function evaluation, and ^{99 m}Tc-DSMA scintigraphy was performed for renal function assessment. Various organs' uptake (%ID/g) of ¹²⁵I-OI5V was estimated in the rats before and at three, five, and seven weeks after the injection.</p><p><strong>Results: </strong>No rats died during DOX injections, until eight weeks. The left ventricular cavity volume increased compared to before DOX injection at five weeks after DOX injection. At seven weeks post-DOX injection, the ejection fraction decreased compared with that before the injection. DMSA scintigraphy revealed that renal function decreased significantly after seven weeks. In the post-mortem tissue counting study, ¹²⁵I-OI5V uptake decreased from five weeks post-injection. After DOX injection, the tracer uptake in the kidney decreased and the tracer uptake in the blood increased.</p><p><strong>Conclusion: </strong>The present study confirmed the expression pattern of σ1R expression after DOX injection. A decrease in σ1R expression detected using ¹²⁵I-OI5V may serve as an earlier marker of DOX-induced cardiotoxicity compared with ejection fraction decline.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which factors affect treatment success/prognosis in thyroid cancers with pulmonary metastases and what is/how should be the effective cumulative cure/dose as a current approach; a retrospective study.","authors":"Fatih Tamer, Mertcan Güven, Aylin Oral, Bülent Yazici, Ayşegül Akgün","doi":"10.1007/s12149-025-02060-5","DOIUrl":"https://doi.org/10.1007/s12149-025-02060-5","url":null,"abstract":"<p><strong>Objective: </strong>Our primary objective in this study was to analyse clinical-prognostic factors, to evaluate their effects on response to radioactive iodine therapy (RAIT) and survival in pulmonary metastatic differantiated thyroid cancer. Another aim was to evaluate the treatment cycles/doses to achieve effective treatment at the end of the follow-up.</p><p><strong>Methods: </strong>68 patients with pulmonary metastatic differentiated thyroid cancer who met all inclusion criteria were included. Clinical-pathological features and imaging findings of patients were collected and analysed retrospectively.</p><p><strong>Results: </strong>Advanced age (p 0.037, OR 1.045), > 2 cm primary tumor (p: 0.009, OR 8), macronodular pulmonary metastases (p: 0.024, OR 3.7) and non-RAI-avidity (p: 0.045, OR 4.5) were independent factors associated with non-response to RAIT. When cumulative RAIT responses in the first 3 cycles were compared, no significant change was observed until the 3rd cycle (up to a cumulative dose of 21.27 GBq). That is, excluding patients who achieved an excellent response in ≤ 2 cycles, it would be appropriate to administer at least 3 cycles (21.27 GBq) to achieve an indeterminate response, which constitutes another pillar of the good prognostic group.</p><p><strong>Conclusion: </strong>Collectively, it would be appropriate to consider that response and survival to RAIT decrease in advanced age and in the presence of macronodular pulmonary metastases. In addition to this, it was concluded that at least 3 cycles of RAIT (21.27 GBq) may be appropriate in the determination of treatment-resistant cases, in other words, in the determination of cases in which biochemical-structural incomplete response can be obtained during follow-up.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of positron emission tomography/magnetic resonance imaging in predicting survival in patients with adenocarcinoma of the esophagogastric junction.","authors":"Gustav Holm Schæbel, Helle Hjorth Johannesen, Johan Löfgren, Henrik Gutte, Lene Bæksgaard, Michael Patrick Achiam, Mohamed Belmouhand","doi":"10.1007/s12149-025-02058-z","DOIUrl":"https://doi.org/10.1007/s12149-025-02058-z","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;In recent years, the utility of positron emission tomography/magnetic resonance imaging (PET/MRI) has become increasingly significant in diagnostic settings. This study provides a five-year follow-up on a previous pilot study that demonstrated the feasibility of PET/MRI in predicting the resectability of adenocarcinoma of the esophagogastric junction (AEG). We aimed to evaluate whether this imaging modality could further serve as a prognostic tool for survival in AEG patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A total of 22 patients were included in the initial pilot study, with 17 of them undergoing surgery. All patients underwent three series of neo-adjuvant chemotherapy (NT). This follow-up study retrospectively analyzed the correlation between the apparent diffusion coefficient (ADC) and standard uptake value (SUV) measurements of the primary tumor from the original study with overall survival and recurrence. ADC and SUV values were measured prior to initiation of NT, and again 17-21 days into the first cycle of NT-administration, and the differences between the scans were calculated as ∆SUV&lt;sub&gt;max&lt;/sub&gt;, ∆ADC&lt;sub&gt;b0&lt;/sub&gt;, and ∆ADC&lt;sub&gt;b50&lt;/sub&gt;. Early treatment response was assessed using the Response Evaluation Criteria In Solid Tumors (RECIST). Binary logistic regression was employed to evaluate the predictive values of ADC and SUV parameters, and receiver operating characteristic (ROC) curves were generated to determine sensitivity, specificity, and area under the curve (AUC).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;As of January 7, 2022, 8 of the 22 patients were still alive. The AUC was calculated to assess the association of imaging parameters with long-term survival: ∆SUV&lt;sub&gt;max&lt;/sub&gt;: AUC = 0.74, sensitivity, 87.5%, specificity 62.5% (p = 0.037). ∆ADC&lt;sub&gt;b0&lt;/sub&gt;: AUC = 0.62, sensitivity 85.7%, specificity 57.1% (p = 0.400). ∆ADC&lt;sub&gt;b50&lt;/sub&gt;: AUC = 0.78, sensitivity 78.6%, specificity 85.7% (p = 0.011). Combining all three parameters yielded an AUC of 0.81, with a sensitivity of 78.6% and a specificity of 85.7% (p = 0.002). The results for individual measurements were: SUV&lt;sub&gt;max&lt;/sub&gt;(pre-NT): AUC = 0.56, sensitivity 78.6%, specificity 50% (p = 0.646). SUV&lt;sub&gt;max&lt;/sub&gt;(post-NT): AUC = 0.81, sensitivity 85.7%, specificity 87.5% (p = 0.002). ADC&lt;sub&gt;b0&lt;/sub&gt;(pre-NT): AUC = 0.55, sensitivity 71.4%, specificity 62.5% (p = 0.682). ADC&lt;sub&gt;b0&lt;/sub&gt;(post-NT): AUC = 0.63, sensitivity 78.6%, specificity 57.1% (p = 0.339). ADC&lt;sub&gt;b50&lt;/sub&gt;(pre-NT): AUC = 0.51, sensitivity 85.7%, specificity 37.5% (p = 0.952). ADC&lt;sub&gt;b50&lt;/sub&gt;(post-NT): AUC = 0.63, sensitivity 42.9%, specificity 100% (p = 0.279). No significant correlation was found between RECIST group and survival status (p = 0.15).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Our results indicate that PET/MRI is feasible for predicting long-term survival in AEG patients. The highest AUCs were achieved when combining SUV and ADC parameters, and when using post-NT SUV&lt;","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A first-in-man PET study of 2-amino-[3-¹¹C] isobutyric acid for the amino acid transport System A: biodistribution and dosimetry in healthy volunteers.","authors":"Kentaro Tamura, Atsushi B Tsuji, Ryuichi Nishii, Kotaro Tani, Hiroki Hashimoto, Kazunori Kawamura, Ming-Rong Zhang, Takamasa Maeda, Kana Yamazaki, Tatsuya Higashi","doi":"10.1007/s12149-025-02059-y","DOIUrl":"https://doi.org/10.1007/s12149-025-02059-y","url":null,"abstract":"<p><strong>Purpose: </strong>This first-in-human study aimed to assess the biodistribution, radiation dosimetry, and safety of the novel PET tracer [3-¹¹C]AIB, a putative System A amino acid transport probe, in healthy volunteers.</p><p><strong>Methods: </strong>Six healthy male participants underwent whole-body PET/CT scans following a rapid intravenous bolus of [3-¹¹C]AIB (injected dose: 366.9 ± 17.9 MBq). Dynamic imaging of the upper abdomen was performed for 4 min post-injection, followed by static whole-body scans up to 90 min. The volumes of interest were drawn on major organs to derive time activity curves for dosimetry calculations. Safety was assessed through vital signs and laboratory tests before and after imaging.</p><p><strong>Results: </strong>High tracer uptake was observed in the salivary glands, pancreas, kidneys, and liver, whereas uptake in the brain and skeletal muscles remained low. The principal route of excretion was via the urinary tract. The effective dose was 5.1 µSv/MBq, corresponding to 1.9 mSv for 370 MBq injection comparable to other 11C-labeled amino acid tracers. No adverse events or significant changes in clinical assessments were noted.</p><p><strong>Conclusions: </strong>This first-in-man evaluation of [3-¹¹C]AIB demonstrated its safety and acceptable radiation dosimetry profile comparable to other ¹¹C-labeled amino acid tracers. The distinct biodistribution pattern with minimal uptake in the brain and skeletal muscles creates high contrast conditions for potential tumor imaging in these regions. The rapid kinetics suggest imaging protocols could be optimized for shorter acquisition times. These characteristics position [3-¹¹C]AIB as a promising radiotracer warranting investigations in cancer types with altered System A amino acid transport and metabolism.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and mechanism of ⁶⁸Ga-FAPI PET/CT in monitoring chemoresistance of non-small cell lung cancer.","authors":"Qian Hua, Ning Wang, Dan Wang, Jun Wen, Baoming Mi","doi":"10.1007/s12149-025-02056-1","DOIUrl":"https://doi.org/10.1007/s12149-025-02056-1","url":null,"abstract":"<p><strong>Background: </strong>Cisplatin-based concurrent chemotherapy is considered first-line treatment for advanced NSCLC. In this study, the role of ⁶⁸Ga-FAPI in visualizing chemotherapy resistance and the regulatory mechanisms which CAFs influence chemoresistance of NSCLC was evaluated.</p><p><strong>Methods: </strong>The CAFs were isolated form fresh NSCLC tissue, and the expression of FAP was evaluated by qRT-PCR and western blotting. ⁶⁸Ga-FAPI micro-PET/CT was performed to visualize CAFs distribution and quantity in vivo. A cytokine array was conducted to analyze the secretion of HGF. The expression of LINC01123 was detected by overlapping high-throughput sequencing results with the analysis of the GEO database (GSE43493). Finally, the interaction between LINC01123 and β-catenin was assessed using RNA pull-down and RIP techniques.</p><p><strong>Results: </strong>In this study, we employed ⁶⁸Ga-FAPI micro-PET/CT to quantify the number of CAFs and visualize the different uptake between cisplatin sensitive and resistant NSCLC xenograft models. The biological role of CAFs in cisplatin treatment for NSCLC was evaluated through functional experiments in vitro and in vivo. Functional assay demonstrated that CAFs secrete HGF which upregulates the expression of LINC01123 in NSCLC cells. LINC01123 directly binds to β-catenin and enhances its transcription activity. The activated HGF/LILNC01123/β-catenin signaling-mediated crosstalk between CAFs and tumor cells drives the chemoresistance of NSCLC.</p><p><strong>Conclusions: </strong>Dysregulated activation of the HGF/LINC01123/β-catenin cascade represents a pivotal pathway through which CAFs interact with NSCLC cells, which enhancing the role of ⁶⁸Ga-FAPI to visualize chemotherapy resistance in patients.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The diagnostic value of whole-body HYNIC-PSMA 11 -Tc [^{99 m}Tc] SPECT/CT scan in early staging of patients with moderate- and high-risk prostate cancer.","authors":"Vahid RoshanRavan, Hamidreza Ghorbani, Salman Soltani, Elham Shabani, Hosein Tanha, Ali Moradi, Kamran Aryana, Hasan Mehrad Majd, Behzad Aminzadeh, Reza Jafaei Daloei, Keyvan Sadri, Mahdi Momen Nejhad, Atena Aghaee","doi":"10.1007/s12149-025-02055-2","DOIUrl":"https://doi.org/10.1007/s12149-025-02055-2","url":null,"abstract":"<p><strong>Objective: </strong>This prospective study aims to compare the diagnostic yield of conventional imaging modalities, including CT scan, bone scan, with ^{99 m}Tc-HYNIC-PSMA-11, in detecting local and distant metastases for initial staging in treatment-naïve, intermediate- to high-risk prostate cancer (PCa) patients. ⁶⁸ Ga-PSMA or 18F-PSMA PET/CT scans are known as the preferred modalities for staging this kind of patients, but there are limited PET/CT facilities in developing countries.</p><p><strong>Materials and methods: </strong>A total of 63 treatment-naïve PCa patients were included in the study for the initial staging. Each patient underwent a chest and abdominopelvic CT scan, bone scan, and ^{99 m}Tc-HYNIC-PSMA-11 imaging. ^{99 m}Tc-HYNIC-PSMA-11 (20-25 mCi) and ^{99 m}TC-MDP (20-25 mCi) were administered intravenously, and imaging was performed 3-4 h post-injection. Nuclear scans included whole-body imaging with SPECT or SPECT/CT phases in two fields (thorax and abdominopelvic), along with imaging of suspicious areas. All images were independently interpreted and analyzed on a patient-based and region-based level.</p><p><strong>Results: </strong>Region-based analysis revealed osseous metastatic regions in 78 (median 0 per patient, range 0-9), 25, and 87 (median 2 per patient, range 0-9) regions in the PSMA-11 scan, CT scan, and bone scan, respectively. CT scan was limited in assessing all nine osseous regions due to its restricted field of view. The positive detection rate for local lymph-node and distant metastases (distant lymphatic, osseous, and visceral) was 18/63 (28.6%) and 23/63 (41.3%) for the PSMA-11 scan, and 20/63 (31.8%) and 27/63 (42.9%) for the CT scan, with no significant difference between the two modalities. Overall, the combined findings of the PSMA-11 scan, CT scan, and bone scan were positive in 31/63 (49.2%), 34/63 (53.9%), and 32/63 (50.8%) patients, respectively. Equivocal findings were reported in 1 PSMA-11 scan, 13 CT scans, and 4 bone scans. When equivocal findings were considered as positive for metastasis, the accuracy, sensitivity, and specificity were 78.2%, 60%, and 96.4% for the PSMA-11 scan; 76.1%, 62.9%, and 89.3% for the CT scan; and 85%, 78.6%, and 91.4% for the bone scan. There was a strong agreement in disease staging and overall findings between the PSMA-11 scan and the combination of CT and bone scans (Ƙ = 0.949 and Ƙ = 0.905, respectively; p < 0.001).</p><p><strong>Conclusion: </strong>The comparable accuracy and high concordance between ^{99 m}Tc-HYNIC-PSMA-11 and conventional CT and bone scans make ^{99 m}Tc-HYNIC-PSMA-11 an effective method for initial staging of intermediate- to high-risk prostate cancer patients.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular imaging using ¹⁸F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB NSCLC.","authors":"Kaiyue Wang, Xiaohan Wang, Xue Meng, Guodong Zhang, Guoxin Cai","doi":"10.1007/s12149-025-02057-0","DOIUrl":"https://doi.org/10.1007/s12149-025-02057-0","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to predict the pathological response of patients with non-small cell lung cancer (NSCLC) in prospective trials of neoadjuvant camrelizumab combined with chemotherapy by integrating the clinical characteristics, PET-associated parameters, and hematological indicators.</p><p><strong>Methods: </strong>A prospective analysis was conducted among 24 patients undergoing surgery after neoadjuvant camrelizumab plus chemotherapy. ¹⁸F-Fluorodeoxyglucose (FDG) scans were performed before and after neoadjuvant therapy (pre-NAT, post-NAT). Tumor and secondary lymphoid organ metabolic parameters, along with circulating inflammatory and immune indicators, were measured and correlated with pathological response. Receiver operating characteristic (ROC) curve was used to assess biomarkers' predictive accuracy.</p><p><strong>Results: </strong>Major pathological response (MPR) and pathological complete response (pCR) were achieved in 45.8% (11/24) and 33.3% (8/24) of patients. Before treatment, patients who achieved a pCR had significantly greater SUVmax values (p = 0.011) than non-pCR patients. After treatment, the MPR group exhibited significantly lower SUVmax values than the non-MPR group (p = 0.048). The rate of change in the SUVmax (ΔSUVmax%) differed significantly between the pCR and non-pCR groups (p = 0.019) and between the MPR and non-MPR groups (p = 0.013). After NAT, the lymph nodes' SUVmax in the ypN0 group was significantly lower than that in the ypN + group (p = 0.032). ROC analysis indicated that pre-NAT SUVmax and ΔSUVmax% best distinguished pCR and MPR patients, respectively, with AUCs of 0.82 (p = 0.012) and 0.80 (p = 0.014).</p><p><strong>Conclusion: </strong>Pre-NAT SUVmax, and ΔSUVmax% are promising biomarkers for predicting pathological response to neoadjuvant camrelizumab and chemotherapy.</p><p><strong>Clinicaltrials: </strong></p><p><strong>Gov id: </strong>NCT06241807.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Test for shortening the computation time for imaging of appearance time for cerebral blood using H₂¹⁵O and positron emission tomography.","authors":"Takuya Kobata, Takashi Norikane, Mitsumasa Murao, Yuri Manabe, Yuka Yamamoto, Katsuya Mitamura, Tetsuhiro Hatakeyama, Keisuke Miyake, Yoshihiro Nishiyama, Nobuyuki Kudomi","doi":"10.1007/s12149-025-02054-3","DOIUrl":"https://doi.org/10.1007/s12149-025-02054-3","url":null,"abstract":"<p><strong>Objective: </strong>Delayed appearance of blood in the brain may be a pathophysiological indicator of stenosis or occlusion. Image computation for blood appearance generally requires considerable time. Therefore, in this study, we aimed to shorten the computation time using several algorithms and tested their accuracy and precision using examination data and simulations, as well as the computation time.</p><p><strong>Methods: </strong>We retrospectively analyzed the images of patients with suspected cerebrovascular disorders who underwent PET study with ¹⁵O-labeled tracers. The blood appearance time images were computed by fitting a stepwise time-shifted tissue curve and applying a single-tissue compartment model with several modes of fixing or not fixing the washout rate and/or blood volume terms. The appearance times in images for these modes were compared with the time obtained by ROI-based non-linear fitting in several brain regions. The effects of noise and parameter fixation are assessed using a simulation study.</p><p><strong>Results: </strong>The computation time was 28.2 ± 6.2 min, 16.6 ± 3.9 min, and 2.6 ± 1.1 min for modes without fixing, with fixing blood volume, and washout rate, respectively. The mean difference in the appearance time against ROI-based non-linear fitting was less than 1 s with a standard deviation (SD) of approximately 2.5 s for those modes. The images obtained were similar for all three modes. The simulation showed that SD on the estimated appearance times were acceptable, namely < 1.5 s, for these modes.</p><p><strong>Conclusion: </strong>This study suggests the possibility of visualizing appearance time images in the brain with a reasonable computation time of approximately 2.5 min at the minimum and 30 min at the most.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation study on accuracy of our newly proposed methods for post-therapeutic liver reserve capacity estimation utilizing ^{99 m}Tc-GSA scintigraphy prior to carbon-ion radiotherapy.","authors":"Kana Yamazaki, Tatsuya Higashi, Ryuichi Nishii, Tamasa Terada, Yoichi Mizutani, Yuki Ogura, Mana Akamatsu, Toshitaka Kuroiwa, Hirokazu Makishima, Masaru Wakatsuki, Hitoshi Ishikawa","doi":"10.1007/s12149-025-02048-1","DOIUrl":"https://doi.org/10.1007/s12149-025-02048-1","url":null,"abstract":"<p><strong>Objective: </strong>Carbon-ion radiotherapy (CIRT) is known as a promising treatment for liver tumors. However, no method has been established for estimating post-therapeutic residual liver reserve capacity (pRLRC). We previously introduced the estimation method of pRLRC using ^{99 m}Tc-galactosyl human serum albumin (^{99 m}Tc-GSA) scintigraphy (Yamazaki method). In this study, we developed \"Yamazaki-variant\" method for pRLRC using dose distribution data of CIRT planning. The purpose of this study was to compare pRLRC calculated by Yamazaki method and Yamazaki-variant in CIRT patients for liver tumors, and to provide the clinical advantages in both methods in terms of estimating ability of pRLRC.</p><p><strong>Methods: </strong>Patients who received CIRT for liver tumors in our hospital and underwent ^{99 m}Tc-GSA scintigraphy before and 3 months after CIRT, and contrast-enhanced liver MRI within 1 month before CIRT were included. A total of 71 patients, 21 additional to the 50 previously reported, were evaluated. The maximal removal rate of ^{99 m}Tc-GSA (GSA-Rmax) was analyzed and the GSA-Rmax of the estimated residual liver (GSA-RL) was calculated using fusion images of MRI and SPECT by Yamazaki method. In Yamazaki-variant, multiple simulations were performed using the dose distribution of the CIRT planning and SPECT fusion images to obtain higher diagnostic accuracy of GSA-RL. Two of these estimates, Validation 1 and Validation 2 by Yamazaki-variant, were used as validation data. GSA-RL and Validation 1 and 2 were compared with GSA-Rmax 3 months after CIRT (post-GSA-Rmax) using linear regression analysis.</p><p><strong>Results: </strong>GSA-RL, Validation 1 and 2 were calculated as 0.448 ± 0.214, 0.413 ± 0.199 and 0.435 ± 0.208 mg/min, respectively. Post-GSA-Rmax was 0.428 ± 0.220 mg/min. The relationship between post-GSA-Rmax and each parameter was y = 0.02 + 0.90x (R² = 0.78) for GSA-RL, y = 0.02 + 0.94x (R² = 0.79) for Estimation 1, y = 0.02 + 0.99x (R² = 0.80) for Estimation 2, respectively (P <.0001). Both Yamazaki method and Yamazaki-variant showed comparable accurate estimation ability for post-GSA-Rmax.</p><p><strong>Conclusions: </strong>The estimation of pRLRC by Yamazaki method and Yamazaki-variant was in good agreement with post-therapeutic liver reserve capacity after CIRT, and there was no difference in the accuracy of the estimation. The usefulness of Yamazaki method, which is simpler and more clinically applicable, was confirmed.</p><p><strong>Trial registration: </strong>This study is registered in UMIN Clinical Trials Registry (UMIN-CTR) as UMIN study ID: UMIN000038328 and UMIN000049770, UMIN000038174.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143951940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison and cutoff values of two amyloid PET scaling methods: centiloid scale and amyloid-β load.","authors":"Ryo Yamakuni, Mitsunari Abe, Naoyuki Ukon, Hiroshi Matsuda, Harumasa Takano, Nobukatsu Sawamoto, Atsushi Shima, Yuhei Mori, Hirofumi Sekino, Shiro Ishii, Kenji Fukushima, Toshiki Mizuno, Jin Narumoto, Takashi Hanakawa, Hiroshi Ito","doi":"10.1007/s12149-025-02051-6","DOIUrl":"https://doi.org/10.1007/s12149-025-02051-6","url":null,"abstract":"<p><strong>Objective: </strong>To enhance amyloid-β (Aβ) positron emission tomography (PET) diagnostic accuracy and adjust for tracer differences, the amyloid-β load (Aβ_L) and centiloid (CL) scale were developed. However, the correlation and superiority of these indicators remain unclear. This study aimed to elucidate the correlation and determine cutoff values.</p><p><strong>Methods: </strong>Data from 281 consecutive participants (144 males; mean age, 69.6 years) in the Parkinson's and Alzheimer's Disease Dimensional Neuroimaging Initiative study were analyzed. Initial data, including Aβ PET, structural MRI, and Global Clinical Dementia Rating (G-CDR) scores, were reviewed. CL was calculated using the cerebral cortical and striatum Volume of Interest templates (VOI) and whole cerebellum VOI. Aβ_L was calculated using voxel-wise regression with two canonical images representing non-displaceable and specific binding. Visual estimation was performed by five radiologists, with two independently classify as visual-only Aβ-negative or Aβ-positive. The discrepancies were resolved through majority consensus involving a third observer. Additional visual estimation was performed for cases with CL value under 10 but visual-only Aβ-positive, and those over 30 but Aβ-negative, by two nuclear medicine radiologists. The discrepancies were resolved through discussion and classify as final Aβ diagnosis negative or positive.</p><p><strong>Results: </strong>CL and Aβ_L correlated linearly (CL = Aβ_L × 2.10-9.40, R² = 0.923). In predicting final Aβ diagnosis negative versus positive, both CL (AUC = 0.996) and Aβ_L (AUC = 0.997) were significant, with no significant differences (P = 0.882). The Youden Index was 23.3 for CL and 15.6 for Aβ_L. In predicting cognitively normal participants (G-CDR = 0) from others, both CL (AUC = 0.687) and Aβ_L (AUC = 0.667) were significant, with no significant differences (P = 0.379). The Youden Index was 11.9 for CL and 11.6 for Aβ_L. Using a non-biased Gaussian mixture model, the normal group's mean and SD were -2.5 (SD = 6.5) for CL and 3.7 (SD = 3.0) for Aβ_L, resulting in 95% limits (mean + 2SD) of 10.4 for CL and 9.7 for Aβ_L.</p><p><strong>Conclusions: </strong>This study demonstrated a high correlation and non-inferiority between CL and Aβ_L.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}